[Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations]

Gastroenterol Clin Biol. 2008 Jan;32(1 Pt. 1):3-7. doi: 10.1016/j.gcb.2007.11.001. Epub 2008 Mar 4.

[Article in French]

Authors

V Boige¹, J-C Barbare, O Rosmorduc; Groupe de travail carcinome hépatocellulaire Prodige-Afef

Collaborators

Groupe de travail carcinome hépatocellulaire Prodige-Afef:
T Aparicio, E Assenat, J-F Blanc, E Boucher, O Bouché, J-P Bronowicki, S Cattan, L Chiche, A Daban, T Decaens, F Degos, S Dominguez, M Ducreux, M Hebbar, B Le Bail, J-L Legoux, G Lledo, P Merle, L Mineur, F Mornex, I Ollivier-Hourmand, J-M Péron, J-L Raoul, J-F Seitz, P Sogni, J Taieb, J-C Trinchet

Affiliation

¹ Département de médecine, institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif cedex, France.

PMID: 18341970
DOI: 10.1016/j.gcb.2007.11.001

No abstract available

Publication types

Practice Guideline

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Benzenesulfonates / adverse effects
Benzenesulfonates / therapeutic use*
Carcinoma, Hepatocellular / drug therapy*
Clinical Protocols
Contraindications
Disease-Free Survival
Humans
Liver Neoplasms / drug therapy*
Neoadjuvant Therapy
Niacinamide / analogs & derivatives
Palliative Care
Phenylurea Compounds
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Pyridines / adverse effects
Pyridines / therapeutic use*
Randomized Controlled Trials as Topic
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors*
Remission Induction
Sorafenib
Survival Rate
raf Kinases / antagonists & inhibitors*

Substances

Antineoplastic Agents
Benzenesulfonates
Phenylurea Compounds
Protein Kinase Inhibitors
Pyridines
Niacinamide
Sorafenib
Receptors, Vascular Endothelial Growth Factor
raf Kinases